Limits...
Glucose abnormalities in Asian patients with chronic hepatitis C.

Bo Q, Orsenigo R, Wang J, Griffel L, Brass C - Drug Des Devel Ther (2015)

Bottom Line: Our results indicated that the prevalence of IFG/T2D was high in both Asian and non-Asian CHC patients (23.0% vs 20.9%), and no significant difference was found between these two populations (adjusted odds ratio: 1.3, 95% confidence interval: 0.97, 1.7; P=0.08).Age, sex, and cirrhosis status were risk factors for IFG/T2D in both populations, while body mass index was positively associated with IFG/T2D in non-Asian but not in Asian participants.No significant differences in sustained virological response rates were seen between patients with normal fasting glucose and patients with IFG/T2D for both populations.

View Article: PubMed Central - PubMed

Affiliation: Beijing Novartis Pharma Co. Ltd., Shanghai, People's Republic of China.

ABSTRACT
Many studies have demonstrated a potential association between type 2 diabetes (T2D) and hepatitis C virus infection in Western countries, while similar evidence is limited in Asia. We compared the prevalence of glucose abnormalities (impaired fasting glucose [IFG] and T2D) and their risk factors between Asian and non-Asian chronic hepatitis C (CHC) patients, and evaluated whether glucose abnormalities impacted the viral responses to peginterferon plus ribavirin treatment (current standard of care in most Asian countries). This study retrospectively analyzed data of 1,887 CHC patients from three Phase II/III studies with alisporivir (DEB025) as treatment for CHC. The chi-square test was used to compare the prevalence of IFG/T2D between Asian and non-Asian CHC patients, and logistic regression was used to adjust for sex, age, and cirrhosis status. Risk factors for IFG/T2D were evaluated using univariate and multivariate analysis. Our results indicated that the prevalence of IFG/T2D was high in both Asian and non-Asian CHC patients (23.0% vs 20.9%), and no significant difference was found between these two populations (adjusted odds ratio: 1.3, 95% confidence interval: 0.97, 1.7; P=0.08). Age, sex, and cirrhosis status were risk factors for IFG/T2D in both populations, while body mass index was positively associated with IFG/T2D in non-Asian but not in Asian participants. No significant differences in sustained virological response rates were seen between patients with normal fasting glucose and patients with IFG/T2D for both populations. These results demonstrate that the prevalence of glucose abnormalities in Asian CHC patients was similar to that in non-Asians, and glucose abnormalities had no impact on viral response to peginterferon plus ribavirin.

No MeSH data available.


Related in: MedlinePlus

Patients who received peginterferon plus ribavirin and achieved SVR by glucose abnormalities.Abbreviations: IFG, impaired fasting glucose; SVR, sustained virological response; T2D, type 2 diabetes.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4644176&req=5

f1-dddt-9-6009: Patients who received peginterferon plus ribavirin and achieved SVR by glucose abnormalities.Abbreviations: IFG, impaired fasting glucose; SVR, sustained virological response; T2D, type 2 diabetes.

Mentions: In the control arms, genotype 1 naïve or treatment-experienced patients received 48 weeks of treatment with pegIFN once a week plus RBV, while the genotype 2/3 patients received 24 weeks of treatment. SVR data were pooled together and SVR rates were compared by glucose status as well as Asian or non-Asian races (Figure 1). There was 111 Asian and 243 non-Asian patients that were treated with pegIFN/RBV. Both in Asian and non-Asian CHC patients, there were no statistically significant differences in SVR rate between patients with IFG/T2D and those with normal fasting glucose, despite the fact that there were many more treatment-experienced patients in the IFG/T2D group (treatment-experienced patients in the IFG/T2D group vs the normal glucose group for Asian patients: 28.0% vs 5.8%, P=0.002; for non-Asian patients: 24.5% vs 12.6%, P=0.03). When comparing the SVR rates within the same glucose status, the rate in Asian normal fasting glucose participants was as much as 16% higher than in non-Asians (P<0.01), and Asian participants with glucose abnormalities showed a 32% higher SVR rate than non-Asians (P<0.01).


Glucose abnormalities in Asian patients with chronic hepatitis C.

Bo Q, Orsenigo R, Wang J, Griffel L, Brass C - Drug Des Devel Ther (2015)

Patients who received peginterferon plus ribavirin and achieved SVR by glucose abnormalities.Abbreviations: IFG, impaired fasting glucose; SVR, sustained virological response; T2D, type 2 diabetes.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4644176&req=5

f1-dddt-9-6009: Patients who received peginterferon plus ribavirin and achieved SVR by glucose abnormalities.Abbreviations: IFG, impaired fasting glucose; SVR, sustained virological response; T2D, type 2 diabetes.
Mentions: In the control arms, genotype 1 naïve or treatment-experienced patients received 48 weeks of treatment with pegIFN once a week plus RBV, while the genotype 2/3 patients received 24 weeks of treatment. SVR data were pooled together and SVR rates were compared by glucose status as well as Asian or non-Asian races (Figure 1). There was 111 Asian and 243 non-Asian patients that were treated with pegIFN/RBV. Both in Asian and non-Asian CHC patients, there were no statistically significant differences in SVR rate between patients with IFG/T2D and those with normal fasting glucose, despite the fact that there were many more treatment-experienced patients in the IFG/T2D group (treatment-experienced patients in the IFG/T2D group vs the normal glucose group for Asian patients: 28.0% vs 5.8%, P=0.002; for non-Asian patients: 24.5% vs 12.6%, P=0.03). When comparing the SVR rates within the same glucose status, the rate in Asian normal fasting glucose participants was as much as 16% higher than in non-Asians (P<0.01), and Asian participants with glucose abnormalities showed a 32% higher SVR rate than non-Asians (P<0.01).

Bottom Line: Our results indicated that the prevalence of IFG/T2D was high in both Asian and non-Asian CHC patients (23.0% vs 20.9%), and no significant difference was found between these two populations (adjusted odds ratio: 1.3, 95% confidence interval: 0.97, 1.7; P=0.08).Age, sex, and cirrhosis status were risk factors for IFG/T2D in both populations, while body mass index was positively associated with IFG/T2D in non-Asian but not in Asian participants.No significant differences in sustained virological response rates were seen between patients with normal fasting glucose and patients with IFG/T2D for both populations.

View Article: PubMed Central - PubMed

Affiliation: Beijing Novartis Pharma Co. Ltd., Shanghai, People's Republic of China.

ABSTRACT
Many studies have demonstrated a potential association between type 2 diabetes (T2D) and hepatitis C virus infection in Western countries, while similar evidence is limited in Asia. We compared the prevalence of glucose abnormalities (impaired fasting glucose [IFG] and T2D) and their risk factors between Asian and non-Asian chronic hepatitis C (CHC) patients, and evaluated whether glucose abnormalities impacted the viral responses to peginterferon plus ribavirin treatment (current standard of care in most Asian countries). This study retrospectively analyzed data of 1,887 CHC patients from three Phase II/III studies with alisporivir (DEB025) as treatment for CHC. The chi-square test was used to compare the prevalence of IFG/T2D between Asian and non-Asian CHC patients, and logistic regression was used to adjust for sex, age, and cirrhosis status. Risk factors for IFG/T2D were evaluated using univariate and multivariate analysis. Our results indicated that the prevalence of IFG/T2D was high in both Asian and non-Asian CHC patients (23.0% vs 20.9%), and no significant difference was found between these two populations (adjusted odds ratio: 1.3, 95% confidence interval: 0.97, 1.7; P=0.08). Age, sex, and cirrhosis status were risk factors for IFG/T2D in both populations, while body mass index was positively associated with IFG/T2D in non-Asian but not in Asian participants. No significant differences in sustained virological response rates were seen between patients with normal fasting glucose and patients with IFG/T2D for both populations. These results demonstrate that the prevalence of glucose abnormalities in Asian CHC patients was similar to that in non-Asians, and glucose abnormalities had no impact on viral response to peginterferon plus ribavirin.

No MeSH data available.


Related in: MedlinePlus